The tweet was deleted by the author.
But we saved everything 🙂.
Trupanion is celebrating Veterinary Appreciation Day by spotlighting 12 winners in recognition of their impact on veterinary medicine.
The winners are recognized for their heart, resilience, teamwork, and dedication. Trupanion has invited the public to meet the winners through a provided online link.
TRUP is trading at $23.58, sitting above the MA-20 ($22.46) but below the MA-50 ($24.22) and well under the MA-200 ($32.86). This structure points to short-term stabilization but ongoing medium- and long-term bearish pressure. The Ichimoku Kijun at $22.84 is below the current price, serving as immediate support. Near-term support is at $22.84 (Kijun) and $22.46 (MA-20), while near-term resistance comes in at $24.22 (MA-50), with key resistance at $26.17 (MA-100).
On the momentum front, MACD on D1 stands neutral and ADX shows low trend strength, while BBP signals an overbought environment with buyer dominance. RSI on D1 is constructive at 53.2 but Stoch RSI highlights a "Strong Sell" and CCI is flagged as overbought, creating a divergence between momentum and overextension signals. TRUP has declined $0.07 (0.49%) over the past week, closing in the lower part of its recent range, and weekly volatility stands at 6.83%. The tone remains cautious, with prices retreating from the weekly high and consolidating near recent lows.
Looking ahead, the expected range for the coming week is $22.99 to $24.56, adjusted to fit recent volatility and price action, and anchored between the 52-week low of $21.16 and high of $57.89. Based on weekly trends, there is a very low probability (less than 20%) of a significant price increase and a much higher probability of further downside. The baseline scenario anticipates sideways movement between $22.99 and $24.56. A bullish scenario would require a firm breakout above $24.22–$24.56 resistance, while a bearish reversal could trigger a test of supports at $22.84 and $22.46, with a risk of moving closer to year-to-date lows if momentum deteriorates.
Earlier, analysts noted that Trupanion was facing persistent bearish pressure with limited evidence of a near-term recovery. This article builds on that view by assessing whether recent price action signals stabilization or introduces new downside risks, with close attention warranted on any emerging momentum that could challenge the prevailing trend.